Lutetium-labelled Peptides for Therapy of Neuroendocrine Tumours

Overview

Journal Eur J Nucl Med Mol Imaging

Specialties Biophysics
Nuclear Medicine
Radiology

Date 2012 Mar 6

PMID 22388631

Citations 75

Authors

B L R Kam

J J M Teunissen

E P Krenning

W W de Herder

S Khan

E I van Vliet

D J Kwekkeboom

Affiliations

Soon will be listed here.

Abstract

Treatment with radiolabelled somatostatin analogues is a promising new tool in the management of patients with inoperable or metastasized neuroendocrine tumours. Symptomatic improvement may occur with (177)Lu-labelled somatostatin analogues that have been used for peptide receptor radionuclide therapy (PRRT). The results obtained with (177)Lu-[DOTA(0),Tyr(3)]octreotate (DOTATATE) are very encouraging in terms of tumour regression. Dosimetry studies with (177)Lu-DOTATATE as well as the limited side effects with additional cycles of (177)Lu-DOTATATE suggest that more cycles of (177)Lu-DOTATATE can be safely given. Also, if kidney-protective agents are used, the side effects of this therapy are few and mild and less than those from the use of (90)Y-[DOTA(0),Tyr(3)]octreotide (DOTATOC). Besides objective tumour responses, the median progression-free survival is more than 40 months. The patients' self-assessed quality of life increases significantly after treatment with (177)Lu-DOTATATE. Lastly, compared to historical controls, there is a benefit in overall survival of several years from the time of diagnosis in patients treated with (177)Lu-DOTATATE. These findings compare favourably with the limited number of alternative therapeutic approaches. If more widespread use of PRRT can be guaranteed, such therapy may well become the therapy of first choice in patients with metastasized or inoperable neuroendocrine tumours.

Citing Articles

Therapeutic Exploitation of Neuroendocrine Transdifferentiation Drivers in Prostate Cancer.

Maylin Z, Smith C, Classen A, Asim M, Pandha H, Wang Y Cells. 2024; 13(23).

PMID: 39682746 PMC: 11639977. DOI: 10.3390/cells13231999.

Peptide Receptor Radionuclide Therapy Using Y- and Lu-DOTATATE Modulating Atherosclerotic Plaque Inflammation: Longitudinal Monitoring by Ga-DOTATATE Positron Emissions Tomography/Computer Tomography.

Rubinstein G, Ilhan H, Bartenstein P, Lehner S, Hacker M, Todica A Diagnostics (Basel). 2024; 14(22).

PMID: 39594152 PMC: 11593158. DOI: 10.3390/diagnostics14222486.

Activity quantification and dosimetry in radiopharmaceutical therapy with reference to Lutetium.

Ramonaheng K, Qebetu M, Ndlovu H, Swanepoel C, Smith L, Mdanda S Front Nucl Med. 2024; 4:1355912.

PMID: 39355215 PMC: 11440950. DOI: 10.3389/fnume.2024.1355912.

Peptide Therapeutics: Unveiling the Potential against Cancer-A Journey through 1989.

Al Musaimi O Cancers (Basel). 2024; 16(5).

PMID: 38473389 PMC: 11326481. DOI: 10.3390/cancers16051032.

Outcome analysis in patients with metastatic gastroenteropancreatic neuroendocrine tumors receiving peptide receptor radionuclide therapy with Lu-177-DOTATATE.

Pretot D, Engel-Bicik I, Kenkel D, Kaufmann P, Treyer V, Siebenhuner A J Gastrointest Oncol. 2023; 14(3):1204-1217.

PMID: 37435198 PMC: 10331769. DOI: 10.21037/jgo-22-874.

References

Otte A, Herrmann R, Heppeler A, Behe M, Jermann E, Powell P . Yttrium-90 DOTATOC: first clinical results. Eur J Nucl Med. 1999; 26(11):1439-47. View

Sward C, Bernhardt P, Johanson V, Schmitt A, Ahlman H, Stridsberg M . Comparison of [177Lu-DOTA0,Tyr3]-octreotate and [177Lu-DOTA0,Tyr3]-octreotide for receptor-mediated radiation therapy of the xenografted human midgut carcinoid tumor GOT1. Cancer Biother Radiopharm. 2008; 23(1):114-20. DOI: 10.1089/cbr.2007.0421. View

Bodei L, Cremonesi M, Grana C, Fazio N, Iodice S, Baio S . Peptide receptor radionuclide therapy with ¹⁷⁷Lu-DOTATATE: the IEO phase I-II study. Eur J Nucl Med Mol Imaging. 2011; 38(12):2125-35. DOI: 10.1007/s00259-011-1902-1. View

de Jong M, Breeman W, Valkema R, Bernard B, Krenning E . Combination radionuclide therapy using 177Lu- and 90Y-labeled somatostatin analogs. J Nucl Med. 2005; 46 Suppl 1:13S-7S. View

McStay M, Maudgil D, Williams M, Tibballs J, Watkinson A, Caplin M . Large-volume liver metastases from neuroendocrine tumors: hepatic intraarterial 90Y-DOTA-lanreotide as effective palliative therapy. Radiology. 2005; 237(2):718-26. DOI: 10.1148/radiol.2372041203. View

Kwekkeboom D, Bakker W, Kooij P, Konijnenberg M, Srinivasan A, Erion J . [177Lu-DOTAOTyr3]octreotate: comparison with [111In-DTPAo]octreotide in patients. Eur J Nucl Med. 2001; 28(9):1319-25. DOI: 10.1007/s002590100574. View

Valkema R, de Jong M, Bakker W, Breeman W, Kooij P, Lugtenburg P . Phase I study of peptide receptor radionuclide therapy with [In-DTPA]octreotide: the Rotterdam experience. Semin Nucl Med. 2002; 32(2):110-22. DOI: 10.1053/snuc/2002.31025. View

Garkavij M, Nickel M, Sjogreen-Gleisner K, Ljungberg M, Ohlsson T, Wingardh K . 177Lu-[DOTA0,Tyr3] octreotate therapy in patients with disseminated neuroendocrine tumors: Analysis of dosimetry with impact on future therapeutic strategy. Cancer. 2010; 116(4 Suppl):1084-92. DOI: 10.1002/cncr.24796. View

Limouris G, Chatziioannou A, Kontogeorgakos D, Mourikis D, Lyra M, Dimitriou P . Selective hepatic arterial infusion of In-111-DTPA-Phe1-octreotide in neuroendocrine liver metastases. Eur J Nucl Med Mol Imaging. 2008; 35(10):1827-37. DOI: 10.1007/s00259-008-0779-0. View

10.

Bodei L, Cremonesi M, Zoboli S, Grana C, Bartolomei M, Rocca P . Receptor-mediated radionuclide therapy with 90Y-DOTATOC in association with amino acid infusion: a phase I study. Eur J Nucl Med Mol Imaging. 2003; 30(2):207-16. DOI: 10.1007/s00259-002-1023-y. View

11.

OMara R, McAfee J, Subramanian G . Rare earth nuclides as potential agents for skeletal imaging. J Nucl Med. 1969; 10(1):49-51. View

12.

Dunst J, Reese T, Sutter T, Zuhlke H, Hinke A, Frings S . Phase I trial evaluating the concurrent combination of radiotherapy and capecitabine in rectal cancer. J Clin Oncol. 2002; 20(19):3983-91. DOI: 10.1200/JCO.2002.02.049. View

13.

Wong J, Shibata S, Williams L, Kwok C, Liu A, Chu D . A Phase I trial of 90Y-anti-carcinoembryonic antigen chimeric T84.66 radioimmunotherapy with 5-fluorouracil in patients with metastatic colorectal cancer. Clin Cancer Res. 2003; 9(16 Pt 1):5842-52. View

14.

de Keizer B, van Aken M, Feelders R, de Herder W, Kam B, Van Essen M . Hormonal crises following receptor radionuclide therapy with the radiolabeled somatostatin analogue [177Lu-DOTA0,Tyr3]octreotate. Eur J Nucl Med Mol Imaging. 2008; 35(4):749-55. PMC: 2668649. DOI: 10.1007/s00259-007-0691-z. View

15.

Bard D, Knight C, Page-Thomas D . Effect of the intra-articular injection of lutetium-177 in chelator liposomes on the progress of an experimental arthritis in rabbits. Clin Exp Rheumatol. 1985; 3(3):237-42. View

16.

Khan S, Krenning E, Van Essen M, Kam B, Teunissen J, Kwekkeboom D . Quality of life in 265 patients with gastroenteropancreatic or bronchial neuroendocrine tumors treated with [177Lu-DOTA0,Tyr3]octreotate. J Nucl Med. 2011; 52(9):1361-8. DOI: 10.2967/jnumed.111.087932. View

17.

Kwekkeboom D, Teunissen J, Bakker W, Kooij P, de Herder W, Feelders R . Radiolabeled somatostatin analog [177Lu-DOTA0,Tyr3]octreotate in patients with endocrine gastroenteropancreatic tumors. J Clin Oncol. 2005; 23(12):2754-62. DOI: 10.1200/JCO.2005.08.066. View

18.

Waldherr C, Pless M, Maecke H, Haldemann A, Mueller-Brand J . The clinical value of [90Y-DOTA]-D-Phe1-Tyr3-octreotide (90Y-DOTATOC) in the treatment of neuroendocrine tumours: a clinical phase II study. Ann Oncol. 2001; 12(7):941-5. DOI: 10.1023/a:1011160913619. View

19.

Kwekkeboom D, de Herder W, Kam B, Van Eijck C, Van Essen M, Kooij P . Treatment with the radiolabeled somatostatin analog [177 Lu-DOTA 0,Tyr3]octreotate: toxicity, efficacy, and survival. J Clin Oncol. 2008; 26(13):2124-30. DOI: 10.1200/JCO.2007.15.2553. View

20.

Imhof A, Brunner P, Marincek N, Briel M, Schindler C, Rasch H . Response, survival, and long-term toxicity after therapy with the radiolabeled somatostatin analogue [90Y-DOTA]-TOC in metastasized neuroendocrine cancers. J Clin Oncol. 2011; 29(17):2416-23. DOI: 10.1200/JCO.2010.33.7873. View